February 26, 2009
Urodynamix Technologies Ltd. Receives CE Mark
MMS to launch UroNIRS 2000™ Bladder Monitor System at the Annual EAU in
Stockholm Sweden
VANCOUVER, British Columbia, February 26, 2009 -
Urodynamix Technologies Ltd. (TSXV:URO) today
announced that it has obtained a CE Mark for the
UroNIRS 2000™ Bladder Monitor System and will
officially launch the product in Europe with its
distribution partner Medical Measurement Systems
B.V. (MMS) at the Annual EAU Conference in Stockholm
Sweden March 17 – 21, 2009.
The granting of the CE Mark will allow Urodynamix to
expand distribution of its UroNIRS products into the
urology office and outpatient markets in Europe
where millions of men suffer from the symptoms of
benign prostatic hyperplasia (BPH) and require
effective diagnosis prior to treatment. Urodynamix
expects to commence commercial shipments of UroNIRS
2000 to Europe in the first quarter of 2009.
“The receipt of the CE Mark sets the stage for our
rollout of the uroNIRS technology in Europe. We are
very pleased to have achieved this major milestone.”
said Barry Allen, President and CEO of Urodynamix.
“The UroNIRS 2000 is a key part of our expansion
from the acute care market into the larger office
based urology market and Europe is a major market to
have access to. The UroNIRS 2000 is a user friendly
and cost effective device for the urology office
market where we believe the noninvasive fast
diagnostic procedure will have incredible value."
“MMS is a market leader in urodynamics and we are
looking forward to introducing and promoting this
exciting new technology,” said Arjen J. de Weerd,
President of MMS. “By being able to provide
Urodynamix’s UroNIRS technology on a standalone
basis we will continue to provide the latest
advances in noninvasive diagnostic technology to our
global customer base.”
The UroNIRS 2000 is based on a wireless tablet PC
with Urodynamix’s proprietary sensor configuration.
It is compact, portable and specifically designed
for ease of use in the urologist’s office setting.
The UroNIRS 2000 utilizes a noninvasive procedure to
confirm the presence of bladder outlet obstruction
in men by identifying patients that have healthy
bladder function yet suffer from weak urinary
stream, hesitancy, urinary retention and related
symptoms. UroNIRS 2000 is safer, faster, less
expensive and more comfortable than conventional
catheterbased diagnostics used to identify the same
condition. Clinical studies have shown that the
UroNIRS 2000 device has an 86% success rate for
accurately identifying obstructed male patients,
most of whom are good surgical candidates.
About Medical Measurement Systems B.V.
MMS has been producing urodynamic systems for
more than 20 years, including Solar SmartFlow™
Urodynamics Systems and Flowmaster™ UroFlow
products. MMS has an outstanding reputation for
product development and innovation. Their engineers,
sales and marketing teams have daily contact with
practicing nurses and physicians all over the world,
enabling MMS to develop diagnostic systems that
exactly meet the needs of today’s healthcare
professionals.
The main corporate office of MMS is located in
Enschede, the Netherlands, where all products are
designed and tested to comply with American and
European medical safety regulations as well as
international quality standards. Global distribution
takes place through branch offices in the United
States, Germany and The Netherlands and a worldwide
network of highly qualified distributors who sell
and service MMS systems to university, public and
private hospitals in more than 60 countries.
About Urodynamix Technologies Ltd.
Urodynamix Technologies is a Canadian medical device company developing and commercializing non-invasive medical technology based on proprietary applications of near-infrared spectroscopy (NIRS). The Company is currently focused on products that aid in the diagnosis and treatment of urinary incontinence, lower urinary tract symptoms, prostate cancer, benign prostatic hyperplasia, and traumatic increases in intra-abdominal pressure that cause abdominal compartment syndrome. Urodynamix’s breakthrough medical technology has the potential to beneficially affect more than 200 million people worldwide.
Certain information contained in this press release may be forward-looking and is subject to unknown risks, which could cause actual results to differ materially from those set forth or implied herein. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
For more information, please contact:
Jonathan Jackson
Chief Financial Officer
Urodynamix Technologies Ltd.
Tel: (604) 638-0248
Email: jjackson@urodynamix.com
www.urodynamix.com
|
